3 Publisher’s Note The Lp(a): A Toolkit for Healthcare Professionals is published by Ascend Media, LLC 401 SW Ward Road, Suite 210, Lee’s Summit, MO 64081 © 2026 American Heart Association, Inc., a 501(c)(3) not-for-profit. All rights reserved. Unauthorized use prohibited. All references and data are as of September 2026. Contributing Authors Disclosures Iulia Iatan, MD, PhD, FRCPC Professional Activities – Honoraria: Amgen Canada; HLS Therapeutics; Novartis Pharmaceuticals Canada; Sanofi; Ultragenyx Pharmaceutical Inc. Professional Activities – Advisory Board: Amgen Canada; HLS Therapeutics; Merck; Novartis Pharmaceuticals Canada; Ultragenyx Pharmaceutical Inc. Iulia Iatan, MD, PhD, FRCPC, is an assistant professor at McGill University and clinician-scientist at the Research Institute of the McGill University Health Centre. She specializes in cardiometabolic and vascular prevention with a focus on inherited lipid disorders, including lipoprotein(a) and familial hypercholesterolemia, and women’s cardiovascular health. Her research has received distinctions from the American Heart Association, Canadian Cardiovascular Society, and National Lipid Association. Cindy Lamendola, MSN, ANP, FAHA, FPCNA Professional Activities – Employment: School of Medicine, Stanford University Professional Activities – Research Study: Alnylam Pharmaceuticals, Inc.; Amgen; AMYLX; Novartis Pharmaceuticals Corporation; Novo Nordisk Professional Activities – Research Funds: Ionis; Novo Nordisk Professional Activities – Clinical Trial: Novartis Pharmaceuticals Corporation; Eli Lilly and Company; Intellia Therapeutics Cindy Lamendola, MSN, ANP, FAHA, FPCNA, is an adult nurse practitioner and clinical research nurse manager at Stanford University School of Medicine in Stanford, California. She has focused on risk management of cardiovascular disease and type 2 diabetes. Areas of research include insulin resistance, type 2 diabetes and relationship to cardiovascular disease and lipid abnormalities, including Lp(a). She is a founding member of the Preventive Cardiovascular Nurses Association, and member and fellow of AHA. Marlys Koschinsky PhD, FAHA Professional Activities – Employment: University of Western Ontario Professional Activities – Research Contract: Amgen; Eli Lilly and Company Professional Activities – Consultant: Eli Lilly and Company; Novartis Marlys Koschinsky PhD, FAHA, is a professor of physiology and pharmacology as well as serving as the Scientific and Executive Director for the Robarts Research Institute in the Schulich School of Medicine & Dentistry at Western University in Ontario, Canada. She is a recognized leader in the Lp(a) field and has unraveled many mysteries of this unique lipoprotein. She has national and international collaborations with many stakeholder groups and has helped translate knowledge from the basic biochemistry of Lp(a) to preclinical, clinical and R&D applications. Joseph L. Witztum, MD (1943-2026) Dr. Witztum was a Distinguished Professor of Medicine in the Division of Endocrinology and Metabolism at the University of California in San Diego. For more than 40 years, Dr. Witztum made major contributions to the field of atherosclerosis and lipoprotein metabolism. He was actively involved in basic and clinical studies to develop novel therapies for unmet needs, especially in the context of hypertriglyceridemia and elevated Lp(a) levels. His research resulted in more than 500 manuscripts. Dr. Witztum was a contributing author from this toolkit’s launch in 2020 through its publication in 2025. We’re grateful for his many contributions to the field. Life Career Read more about Dr. Witztum’s life and career. IN MEMORIAM
RkJQdWJsaXNoZXIy MjI2NjI=